The drug operates by binding to the CD30 antigen on the surface of cancer cells. Upon binding, it is internalized by the cell, where the cytotoxic agent MMAE is released. MMAE then disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis (programmed cell death). This targeted approach enhances the efficacy of the treatment while reducing systemic side effects.